Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

94.11 -0.30 (-0.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
52 53 Next >
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Thursday, Gilead Sciences stock had its Relative Strength (RS) Rating upgraded to 81, up from 78 a day earlier. 
Via Investor's Business Daily
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
If the economy falters, these stocks should hold up better than most. 
Via The Motley Fool
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
3 Analyst Upgrades That Smart Investors Won’t Ignore
In many cases, analyst upgrades can point investors to opportunities like the ones in the stocks on this list. 
Via InvestorPlace
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
From Gilead Sciences, Inc.
Via Business Wire
Mount Gilead, NC Author Publishes Children's Book
Take In The Beauty Of Nature And Quiet The Outside World. 
Via PR Leap
A Look Into Gilead Sciences' Debt
Via Benzinga
Looking Into Gilead Sciences's Recent Short Interest
Via Benzinga
Gilead Appoints Cindy Perettie Executive Vice President of Kite
From Gilead Sciences, Inc.
Via Business Wire
GDC Stock Alert: Why Is GD Culture Group Up 106% Today?
GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Why Is Guardforce AI (GFAI) Stock Up Today?
Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering. 
Via InvestorPlace
Gilead Sciences Stock: Bear vs. Bull
The S&P 500 has outperformed Gilead over the past five years. 
Via The Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,300 Today
Via Benzinga
Expert Ratings for Gilead Sciences
Via Benzinga
Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2023. 
Via The Motley Fool
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?
Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares. 
Via InvestorPlace
Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ: DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close... 
Via Benzinga
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
From Arcus Biosciences
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
From Gilead Sciences, Inc.
Via Business Wire
American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. (NASDAQ: GILD) is a very defensive, steady growth play. 
Via Benzinga
2 Magnificent Dividend Stocks to Buy Before the Next Recession
The healthcare sector is a good place to find recession-proof stocks. 
Via The Motley Fool
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
Via Investor Brand Network
Exposures COVID-19
Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years
Should you buy Gilead Sciences stock despite its poor track record? 
Via The Motley Fool
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Exposures COVID-19
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits
Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help... 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.